2016
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. New England Journal Of Medicine 2016, 374: 1321-1331. PMID: 26886418, PMCID: PMC4887756, DOI: 10.1056/nejmoa1506930.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic strokeInsulin resistanceMyocardial infarctionIschemic attackPrimary outcomeRecent ischemic strokeDouble-blind trialFuture cardiovascular eventsHomeostasis model assessmentInsulin resistance indexRisk of strokeEligible patientsNonfatal strokePioglitazone groupCardiovascular eventsCause mortalityPlacebo groupPreventive therapyCerebrovascular diseaseInsulin sensitivityRisk factorsResistance indexHigh riskLower risk
2005
Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome
Drexler AJ, Nesto RW, Abrahamson MJ, Bakris G, Bell D, Brunzell J, Dandona P, Davidson J, Fonseca V, Fowler M, Frye R, Giles T, Haffner S, Hollenberg N, Hsueh W, Law R, Plutzky J, Ratner R, Reusch J, Selwyn A, Sowers J, Wyne K, Young LH. Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome. Metabolic Syndrome And Related Disorders 2005, 3: 147-173. PMID: 18370723, DOI: 10.1089/met.2005.3.147.Peer-Reviewed Original ResearchType 2 diabetesMetabolic syndromeBeta-cell functionCardiovascular effectsEndothelial dysfunctionVascular reactivityInsulin sensitivityFuture cardiovascular eventsAdverse clinical eventsCoronary artery diseasePositive cardiovascular effectsCardiovascular disease burdenPotential adverse eventsProgression of diabetesInsulin-sensitizing effectsCardiovascular eventsCardiovascular outcomesAdverse eventsCardiovascular riskArtery diseaseGlycemic controlClinical eventsInsulin resistanceDisease burdenRisk factors
2004
Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics–Brachial Artery Reactivity study)
Papaioannou GI, Seip RL, Grey NJ, Katten D, Taylor A, Inzucchi SE, Young LH, Chyun DA, Davey JA, Wackers FJ, Iskandrian AE, Ratner RE, Robinson EC, Carolan S, Engel S, Heller GV. Brachial artery reactivity in asymptomatic patients with type 2 diabetes mellitus and microalbuminuria (from the Detection of Ischemia in Asymptomatic Diabetics–Brachial Artery Reactivity study). The American Journal Of Cardiology 2004, 94: 294-299. PMID: 15276091, DOI: 10.1016/j.amjcard.2004.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAlbuminuriaBrachial ArteryCoronary Artery DiseaseC-Reactive ProteinDiabetes Mellitus, Type 2Diabetic AngiopathiesEndothelium, VascularFemaleHumansLinear ModelsMaleMiddle AgedMultivariate AnalysisProspective StudiesReference ValuesRisk AssessmentSensitivity and SpecificitySeverity of Illness IndexSex FactorsUltrasonography, DopplerVasoconstrictionVasodilationConceptsEndothelium-independent vasodilationEndothelium-dependent vasodilationBrachial artery reactivityType 2 diabetes mellitusHormone replacement therapyDiabetes mellitusC-reactive proteinSystemic inflammationAsymptomatic patientsEndothelial dysfunctionIndependent predictorsReplacement therapyNovel atherosclerotic risk factorAsymptomatic Diabetics (DIAD) studyAtherosclerotic risk factorsPresence of microalbuminuriaFuture cardiovascular eventsSimilar baseline characteristicsDetection of ischemiaCardiovascular eventsBaseline characteristicsBrachial arteryVascular dysfunctionEntire cohortRisk factors